Fasenra®

Understanding Fasenra® 

Fasenra® (benralizumab) is a monoclonal antibody used to treat severe eosinophilic asthma. It works as an interleukin-5 (IL-5) receptor antagonist, targeting and reducing eosinophils, a type of white blood cell that contributes to airway inflammation in asthma patients. By lowering eosinophil levels, Fasenra® helps decrease inflammation, reduce asthma attacks, and improve breathing. It is typically administered as an injectable therapy every 8 weeksafter an initial loading phase.

How Fasenra® Works:

• Targets and reduces eosinophils to decrease airway inflammation.
• Reduces the frequency of asthma attacks in eosinophilic asthma patients.
• Improves lung function and helps patients breathe more easily.

FDA Approval:

• November 14, 2017 – Approved for the treatment of severe eosinophilic asthma

For more information, please visit the Fasenra® patient website and speak with your healthcare provider to determine if Fasenra® is the right treatment option for you.